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Abstract Extracellular cysteine proteases, in particular cathep-
sin B, have been implicated in a variety of pathological pro-
cesses. Selectively targeting labels of this enzyme are important
tools to gain more detailed understanding of its specific roles.
Starting from our recently developed irreversible epoxysuccinyl-
based inhibitor (R-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OH,
R = OMe), we have synthesized two affinity labels, R = NH-
(CH2)6-NH-rhodamine B and R = NH-(CH2)6-NH-biotin. Using
MCF-7 cells, the labeled inhibitors were shown to be virtually
non-cell-permeant. Moreover, affinity blot analysis with the bio-
tinylated inhibitor allowed a highly sensitive and selective non-
radioactive detection of active cathepsin B. ß 2000 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
The lysosomal cysteine proteinase cathepsin B has been
implicated in various pathological processes like in£ammatory
airway diseases [1], bone and joint disorders [2], as well as
cancer progression and metastasis [3^5]. In most of these pro-
cesses, cathepsin B has been found in the extracellular space,
frequently associated with the plasma membrane [6^8]. To
understand the role of this enzyme in pathological processes
in more detail, irreversible inhibitors are desirable that selec-
tively recognize and label extracellular, active cathepsin B.
Until now, biotinylated [9] and radioactive iodinated [10] pep-
tidyl diazomethanes have been described as a⁄nity labels for
active cathepsin B. The iodinated diazomethanes are cell-per-
meant; no cell permeation studies have been reported for the
biotinylated compounds. However, not all diazomethane in-
hibitors achieve the selectivity of epoxysuccinyl peptides of the
CA030/CA074 type.
Already in 1991 Katunuma’s group showed that the
CA030/CA074 derivatives are strictly speci¢c inhibitors for
cathepsin B in vitro and in vivo [11^13]. This high degree of
selectivity was explained later by crystal structures of cathep-
sin B complexed with CA030 [14] and CA074 [15] revealing an
opposite binding mode compared to that of E-64 [16] and a
strong interaction of the Pro carboxylate with the two His
residues of the ‘occluding loop’ of cathepsin B.
Attempting to combine the structural and binding charac-
teristics of E-64- and CA074-type inhibitors in ‘chimeric’ con-
structs we found that the requirements for optimal interaction
with the S and SP subsites are not simply additive and are
strongly dependent on the absolute con¢guration of the epoxy-
succinyl group [17]. By elongation of the CA030-like frag-
ment HO-(2S,3S)-tEps-Leu-Pro-OH with the cathepsin B pro-
peptide-derived fragment Leu-Gly-Gly (amino acids 46^48 of
the propeptide), a very potent and selective cathepsin B inhib-
itor was obtained [18]. According to modeling studies, the
propeptide portion of the inhibitor MeO-Gly-Gly-Leu-
(2S,3S)-tEps-Leu-Pro-OH (8) bridges the whole non-primed
subsite whereas the terminal glycine residue is located on
the surface of the enzyme and thus should allow further func-
tionalization with e¡ector groups without a¡ecting its inhib-
itory potency (Fig. 1). This working assumption was fully
con¢rmed by the conjugate of L-cyclodextrin with MeO-
Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OH (8) as a cathepsin B-
selective drug carrier system [19]. Indeed, the observed second
order rate constant for the conjugate was only slightly de-
creased in comparison to the parent inhibitor. These results
were the incentive to use this type of irreversible cathepsin B
inhibitor as a basis for the design of a⁄nity labels.
In the present communication the synthesis and functional
characterization of a rhodamine B-labeled as well as a bio-
tinylated endo-epoxysuccinyl peptide is described. Both com-
pounds proved to be potent, highly selective and non-cell-per-
meable cathepsin B inhibitors.
2. Materials and methods
2.1. Materials and instruments
All reagents and solvents were of the highest quality commercially
available. Rhodamine B isothiocyanate (mixed isomers) was pur-
chased from Sigma (Munich, Germany), Z-OSu and DBSI from Flu-
ka (Buchs, Switzerland).
TLC was carried out on silica gel 60 plates (Merck AG, Darmstadt,
Germany) and compounds were visualized by chlorine/o-toluidine.
Analytical HPLC was performed with Waters equipment (Eschborn,
Germany) on Nucleosil 300/C18 (Macherey and Nagel, Du«ren, Ger-
many) using a linear gradient of MeCN/2% H3PO4 from 5:95 to
80:20 in 12 min unless otherwise stated, preparative HPLC on Nucle-
osil 100-5 C18 (Macherey and Nagel), and medium pressure reverse
phase chromatography on Lichroprep RP-8 (Merck). NMR spectra
were recorded on Bruker AMX500, FAB-MS spectra on Finnigan
MAT 900 and ESI-MS on PE SICEX API 165.
Human cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.15)
were purchased from Calbiochem (Bad Soden/Taunus, Germany),
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Z-Phe-Arg-NHMec from Bachem (Heidelberg, Germany), DMEM
medium from Biochrom KG (Berlin, Germany) and MCF-7 cells
from the European Collection of Cell Cultures (Salisbury, UK).
2.2. Synthesis of endo-epoxysuccinyl peptide-derived active site labels
2.2.1. HO-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OtBu (2). To a so-
lution of MeO-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OtBu (1) [14] (0.20
g, 0.312 mmol) in THF (12 ml) at 0‡C, 0.1 N NaOH (3.5 ml) was
added. After 3 h the solvent was removed in vacuo. The residue was
dissolved in water, acidi¢ed with 5% KHSO4 and extracted with
AcOEt. The combined organic layers were washed with brine, dried
(Na2SO4) and evaporated. Compound 2 was isolated by precipitation
from AcOEt/petroleum ether; yield: 0.15 g (75%); TLC (CHCl3/
MeOH, 4:1) Rf 0.30; FAB-MS: m/z 626.2 [M+H] ; calcd. for
C29H47N5O10 : 625.3.
2.2.2. Z-NH-(CH2)6-NH2UDBSI (3). To a solution of 1,6-di-
aminohexane (4.66 g, 40.1 mmol) in dioxane (750 ml), Z-OSu (1.00 g,
4.01 mmol) dissolved in dioxane (200 ml) was added within 4 h. The
precipitate was ¢ltered o¡, and the solvent evaporated. The residue
was dissolved in water (100 ml) and extracted with AcOEt (5U50 ml).
The combined organic layers were washed with brine (3U50 ml),
dried (Na2SO4) and evaporated. The residual oil was dissolved in a
small amount of MeOH, and DBSI (1.13 g, 3.80 mmol) was added.
The salt was precipitated with diisopropyl ether; yield: 1.70 g (73%);
TLC (n-BuOH/AcOH/H2O/AcOEt, 3:1:1:5) Rf 0.33; ESI-MS: m/z
251.0 [M+H] ; calcd. for C14H22N2O2 : 250.1.
2.2.3. Z-NH-(CH2)6-NH-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OtBu
(4). To a solution of compound 3 (0.60 g, 1.03 mmol) in CHCl3 (10
ml) neutralized with NMM (114 Wl, 1.03 mmol) and compound 2
(0.50 g, 0.79 mmol), EDC (0.20 g, 1.03 mmol)/HOBt (0.11 g, 0.79
mmol) were added. After 12 h, the solvent was evaporated and the
residual oil dissolved in AcOEt. The organic layer was washed with
5% KHSO4, 5% NaHCO3 and brine, dried (Na2SO4) and evaporated.
The crude product was puri¢ed by £ash chromatography (silica gel
60, eluent CHCl3/MeOH, 9:1). Compound 4 was isolated by precip-
itation from AcOEt/petroleum ether; yield: 0.42 g (62%); TLC
(CHCl3/MeOH, 9:1) Rf 0.43; TLC (n-BuOH/AcOH/H2O/AcOEt,
3:1:1:5) Rf 0.84; ESI-MS: m/z 858.4 [M+H] ; calcd. for
C43H67N7O11 : 857.4.
2.2.4. H2N-(CH2)6-NH-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OtBuU
HOAc (5). Compound 4 (0.10 g, 0.117 mmol) was hydrogenated
over 10% Pd-C in MeOH (50 ml) in the presence of AcOH (75 Wl).
After 30 min, the catalyst was ¢ltered o¡ and the solvent evaporated.
The title compound was isolated by precipitation from MeOH/diiso-
propyl ether as a colorless solid; yield: 0.072 g (78%); TLC (n-BuOH/
AcOH/H2O/AcOEt, 3:1:1:5) Rf 0.17; HPLC tR 8.2 min; ESI-MS:
m/z 724.2 [M+H] ; calcd. for C35H61N7O9 : 723.4.
2.2.5. Rhodamine B-NH-(CH2)6-NH-Gly-Gly-Leu-(2S,3S)-tEps-
Leu-Pro-OHUTFA (6). To a suspension of 5 (28.3 mg, 0.036
mmol) in dioxane (1 ml), 0.1 N NaHCO3 (0.36 ml) was added fol-
lowed by rhodamine B isothiocyanate (28.9 mg, 0.054 mmol) sus-
pended in a mixture of dioxane (2 ml) and 0.1 N NaHCO3 (1.08
ml). After stirring overnight at room temperature, the solvent was
evaporated and the residue dissolved in CHCl3. The organic layer
was washed with water, dried (Na2SO4) and evaporated. The crude
product was dissolved in ice-cold 90% TFA (10 ml) and stirred for 3 h.
The solvent was removed in vacuo and the residual oil was treated
twice with toluene. Upon precipitation from MeOH/diisopropyl ether,
the crude product was puri¢ed by medium pressure reverse phase
chromatography (isocratic elution with MeCN/water, 20:80 (0^10
min), followed by a linear gradient of MeCN/water from 20:80 to
80:20 (10^130 min), and ¢nally isocratic elution with MeCN/water,
80:20 (130^230 min)). Chromatographically homogeneous fractions
were pooled and lyophilized; yield: 10.8 mg (23%) as a 1:1 mixture
of the rhodamine B regioisomers; HPLC (Nucleosil 300/C8, linear
gradient of MeCN/2% H3PO4 from 5:95 to 80:20 in 30 min): tR
23.6 min/24.1 min; ESI-MS: m/z 1168.0 [M+H] ; calcd. for
C60H82N10O12S: 1166.5.
2.2.6. Biotinyl-NH-(CH2)6-NH-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pr-
o-OH (7). To a solution of 5 (72.0 mg, 0.091 mmol) in DMF (3 ml),
DIEA (16 Wl, 0.091 mmol) and biotin N-hydroxysuccinimide ester [20]
(46.6 mg, 0.136 mmol) in DMF (2 ml) were added. After stirring
overnight at room temperature, the solvent was removed in vacuo,
and the residual oil treated with AcOEt. The precipitate was collected
by centrifugation and washed successively with tert.-butyl methyl
ether and petroleum ether. The crude product was dissolved in ice-
cold 95% TFA (5 ml), after 3.5 h, the acid was evaporated and the
residual oil treated twice with toluene. The crude 7, isolated by pre-
cipitation from AcOEt/petroleum ether, was puri¢ed by preparative
HPLC (isocratic elution with 0.1% aqueous TFA/MeCN, 95:5 (0^5
min), followed by a linear gradient of 0.1% aqueous TFA/MeCN
from 95:5 to 82:18 (5^10 min), ¢nally followed by a linear gradient
of 0.1% aqueous TFA/MeCN from 82:18 to 40:60 (10^90 min)). The
homogeneous fractions were pooled and lyophilized; yield: 43.0 mg
(58%); amino acid analysis of the acid hydrolysate (6 M HCl, 110‡C,
72 h): Gly 1.97 (2), Leu 2.03 (2), Pro 1.00 (1), peptide content: 80.3%;
HPLC: tR 7.0 min; ESI-MS: m/z 894.8 [M+H] ; calcd. for
C41H67N9O11S: 893.4.
2.3. NMR spectroscopy
NMR spectra of biotinyl-NH-(CH2)6-NH-Gly-Gly-Leu-(2S,3S)-
tEps-Leu-Pro-OH (7) were recorded at 500 MHz in DMSO-d6 (5
mM). For 1D and 2D proton spectra, the following parameters
were used: 1D-1H-NMR: 64 acquisitions, size 16 K, sweep width
7002.8 Hz; TOCSY [21,22]: mixing time for MLEV17 76 ms, trim
pulse 2.5 ms, size 2 K, sweep width 7002.8 Hz in t1 and t2, 64 acquis-
itions, 512 increments [23]; NOESY [24]: mixing time 200 ms, size
2 K, sweep width 7002.8 Hz in t1 and t2, 64 acquisitions, 512 incre-
ments [23] ; prior to transformation of the TOCSY and NOESY spec-
tra, gaussian window function in t2 and shifted sine-bell function in t1
were used.
2.4. Enzyme inhibition assays
Continuous £uorimetric assays were performed and evaluated as
described in detail elsewhere [18].
2.5. Cell permeability assay
MCF-7 cells were maintained in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM), supplemented with essential amino acids, 1 mM py-
ruvate, 10 Wg/ml insulin and 10% calf serum, in a humidi¢ed CO2
incubator at 37‡C and 5% CO2. For the experiments cells were grown
in 24-well plates where they reached con£uence within a week (from
initial 2U104 cells/well to approx. 2U106 cells/well). After washing
the cells three times with serum-free medium (SFM) at 37‡C, they
were incubated at 37‡C with 300 Wl of SFM containing 1% DMSO
without or with inhibitors for 30 min. Thereafter, cells were washed
Fig. 1. Design concept of endo-epoxysuccinyl peptide-derived a⁄nity labels. Schematic representation of the proposed binding mode of the la-
bels (the e¡ector group is rhodamine B (6) or biotin (7)).
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¢ve times with phosphate-bu¡ered saline at room temperature, and
lysed by treatment with 200 Wl lysis bu¡er (0.5% Triton X-100, 50 mM
sodium acetate, pH 5.5, 2 mM EDTA) for 30 min at room temper-
ature. The residual cathepsin B activity in the lysates was determined
with the £uorogenic substrate Z-Phe-Arg-NHMec followed by inhibi-
tion with the cathepsin B-speci¢c inhibitor 8 (50 nM).
2.6. Fluorimetric determination of rhodamine
The £uorescence of the rhodamine B-labeled inhibitor 6 was mea-
sured at 554 nm excitation and 571 nm emission in a spectro£uorim-
eter Fluoro Max 1 (Instruments S.A.). The £uorescence was linear
with inhibitor concentration after blank subtraction. After calibration
with 1^30 nM inhibitor in 1.5 ml of 0.25 M sodium acetate pH 5.5,
the rhodamine B concentration was determined in 0.1 ml of the lysates
(diluted with 1.4 ml sodium acetate bu¡er, pH 5.5) of MCF-7 cells
that had been incubated with inhibitor 6 before lysis (0^50 WM, see
Section 2.5).
2.7. A⁄nity blots
Lysates from MCF-7 cells (200 Wl) incubated with biotinylated in-
hibitor 7 were precipitated with 3.3% TCA, washed twice with acetone
and dissolved in Laemmli bu¡er containing 2-mercaptoethanol. Puri-
¢ed human liver cathepsin B labeled with the biotinylated inhibitor 7
was used as control. After electrophoresis in 12.5% (w/v) polyacryl-
amide gel slabs, the proteins were transferred to nitrocellulose mem-
branes (Protran, Schleicher and Schuell) by a semidry electrotransfer
procedure [25] in a MilliBlot-SDE System (Millipore) for 45 min at 30
mA. The biotin-labeled proteins were visualized by the avidin/bio-
tinylated peroxidase system, Vectastain ABC Elite (Vector Laborato-
ries) using diaminobenzidine as substrate. In control blots, the bands
were stained additionally with anti-cathepsin B, a polyclonal IgG
from rabbit (Calbiochem), and a second biotinylated antibody from
goat (Vector Laboratories) before incubation with avidin/biotinylated
peroxidase.
3. Results and discussion
3.1. Synthesis and characterization of the functionalized
inhibitors
Starting point for the synthesis was the orthogonally pro-
tected inhibitor 1 [18] (Scheme 1). Upon saponi¢cation of the
methyl ester, the free carboxylic acid 2 was coupled with
mono-Z-protected 1,6-diaminohexane as an additional £exible
spacer to avoid steric clashes of the e¡ector group with the
surface of the enzyme. The hydrogenolytic cleavage of the
benzyloxycarbonyl group was carried out under strictly con-
trolled conditions to avoid opening of the oxirane ring that we
had observed in contrast to reports of Huang et al. [26] in the
case of prolonged hydrogenation. The resulting spacer-func-
tionalized inhibitor 5 was then reacted with rhodamine B iso-
thiocyanate (1:1 mixture of both regioisomers) or with biotin
activated as N-hydroxysuccinimide ester (Scheme 2). The ¢nal
acidolytic cleavage of the tert.-butyl ester protection yielded
the labeled endo-epoxysuccinyl peptides 6 and 7 as homoge-
neous compounds as assessed by HPLC and ESI-MS.
The biotinylated endo-epoxysuccinyl peptide 7 was further
analyzed by 2D-NMR spectroscopy. The TOCSY and NO-
ESY spectra recorded in DMSO-d6 allowed the full assign-
ment of the peptide portion as well as of the biotin label
(Table 1). The observed intra- and interresidual NOEs within
the spacer and/or biotin region displayed a negative sign with
respect to the diagonal indicating a high degree of £exibility of
this part of the molecule.
Scheme 1. Synthesis of the spacer-functionalized endo-epoxysuccinyl peptide. Reaction conditions: (i) NaOH/THF/H2O; (ii) Z-NH-(CH2)6-
NH2UDBSI (3)/NMM/EDC/HOBt/CHCl3 ; (iii) 10% Pd-C/H2/MeOH/AcOH.
Scheme 2. Synthesis of the labeled endo-epoxysuccinyl peptides. Reaction conditions: (i) rhodamine B isothiocyanate/NaHCO3/dioxane/H2O;
(ii) 90% TFA; (iii) biotin N-hydroxysuccinimide ester/DIEA/DMF; (iv) 95% TFA.
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3.2. Inhibitory properties
A comparison of the second order rate constants for inhi-
bition of cathepsin B by the parent inhibitor 8 and the con-
jugates 6 and 7 (Table 2) shows that the inhibitory potency is
not a¡ected by the functionalization of the inhibitor. The
selectivity of the a⁄nity labels 6 and 7 vs. cathepsin L is
even slightly increased, and reaches a value of 6742 in the
case of the biotinylated inhibitor. These data indicate that
the terminal glycine is an optimal site for attaching e¡ector
groups via a spacer and con¢rm our design concept (Fig. 1).
3.3. Cell permeability
The cell permeability of the parent inhibitor 8 as well as of
the conjugates 6 and 7 was assessed using MCF-7 breast can-
cer cells (Fig. 2). No or only slight reduction of cathepsin B
activity was found in the lysates after incubation of the cells
with 0.1 and 1.0 WM of the endo-epoxysuccinyl peptides 6, 7
and 8. Not more than 50^70% of the cathepsin B activity was
blocked in cells incubated with an inhibitor concentration of
10 WM, and even at 50 WM inhibitor approx. 10% of the ca-
thepsin B activity remained detectable in the cell lysates (Fig.
2A). In comparison, despite its lower speci¢city and reactivity
[13] E-64d (1 WM) blocked intracellular cathepsin B activity by
approx. 90% (data not shown). Taking into account that a
low nM concentration of inhibitors 6, 7 and 8 is su⁄cient to
completely inhibit isolated cathepsin B as well as the cathepsin
B activity in lysates of MCF-7 cells within minutes (as shown
in Fig. 2B for inhibitor 8), both the parent inhibitor 8 and the
a⁄nity labels 6 and 7 can be considered to be virtually non-
cell-permeant. This was con¢rmed by direct measurements of
rhodamine £uorescence in the lysates: after calibration with
the rhodamine-labeled inhibitor 6 as a standard, the concen-
tration of free plus enzyme-bound inhibitor 6 in the cell ly-
sates was calculated (Table 3). These concentrations were less
than 0.5% of those in the cell culture medium and correlate
well with the observed degree of cathepsin B inhibition (see
Fig. 2A).
3.4. A⁄nity blots with the biotinylated inhibitor
The applicability of the biotinylated inhibitor 7 for a⁄nity
blotting was investigated with isolated human liver cathepsin
B and with the cell lysates from the permeability studies.
Lanes 3^5 in the blot (Fig. 3) show two bands with molecular
masses of approximately 31 and 5 kDa, respectively. Both
bands were colocalized with those detected by immunoblot
with a polyclonal cathepsin B antibody (data not shown).
As expected for an a⁄nity label that covalently binds to the
active site Cys29 of cathepsin B, both the single-chain form
(31 kDa) as well as the light chain (5 kDa) of the double-chain
form were detected [27,28]. Once covalently attached via a
thioester bond to the active site cysteine of cathepsin B, the
biotinylated inhibitor 7 apparently is able to interact with
avidin without signi¢cant steric hindrance. This is in agree-
ment with the results from the NOESY spectrum of the con-
jugate 7 (see Section 3.1) indicating that the portion of the
molecule containing the spacer and the biotin moiety is fully
£exible in comparison to the epoxysuccinyl peptide portion.
The sensitivity of the a⁄nity label was assessed with decreas-
ing amounts of isolated human liver cathepsin B (Fig. 3, lanes
3^5). Considering the composition of the cathepsin B prepa-
Table 1
Chemical shifts [ppm] of the biotin-functionalized endo-epoxysuccinyl peptide 7 in DMSO-d6
Amino acid residue NH CKH Others
Gly1 7.51 3.13
Gly2 7.88 3.18
Leu1 8.06 3.85 CLH/CQH: 0.99, 1.08; CNH: 0.35
Leu2 8.23 4.10 CLH/CQH: 0.98, 1.14; CNH: 0.39
Pro 3.73 CL1H: 1.62; CL2H: 1.33; CQH: 1.42; CN1H: 3.18; CN2H: 3.00, COOH : 11.90
CH-tEps 3.08, 3.10
Spacer 7.20 CH2NH: 2.50; ^(CH2)4^: 0.86, 0.72
Biotin 5.83, 5.90 CKH: 1.53; CLH/CQH/CNH: 0.76, 0.96, 1.10; COH: 2.57, COHP : 2.06, 2.30; CjH:
3.61; CjHP : 3.79
Table 2
Second order rate constants of inactivation of cysteine proteases by epoxysuccinyl peptide-derived a⁄nity labels
Inhibitor Cathepsin B (CB)
k2/Ki [M31 s31]
Cathepsin L (CL)
k2/Ki [M31 s31]
Ratio CB/CL
Rhodamine B-NH-(CH2)6-NH-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OH (6) 1 530 000 þ 83 500 323 þ 30 4736
Biotin-NH-(CH2)6-NH-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OH (7) 1 726 000 þ 40 900 256 þ 14 6742
MeO-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OH (8) 1 520 000 þ 88 800 1204 þ 29 1262
k2/Ki values were determined in 250 mM sodium acetate bu¡er pH 5.5, þ S.D. from 7^10 experiments and are corrected for substrate competi-
tion; data for compound 8 are from [18].
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ration (ca. 15% single-chain and 85% double-chain form),
about 3 ng of the single-chain form (31 kDa) was detectable
in the blot (Fig. 3, lane 5). This sensitivity of active site label-
ing was similar to the sensitivity of immunoblots performed
with a polyclonal cathepsin B antibody and a biotinylated
second antibody using the same detection system (data not
shown).
In the lysates from the cell permeability experiments (lanes
6^10), the 31 kDa band as well as the light chain (5 kDa) were
detected under reducing conditions. The observed staining is
in good agreement with the cathepsin B activity in the lysates
(see Section 3.3). Furthermore, the blotting results with the
lysates of the cell penetration studies con¢rm the high degree
of selectivity anticipated from inhibition kinetics. No addi-
tional bands were found in the a⁄nity blots. However, this
does not de¢nitely exclude the possibility that the cathepsin B
inhibitors can bind to one of the new thiol cathepsins that
have been discovered more recently [29] and might not be
expressed in MCF-7 cells. A putative target might be cathep-
sin X which has been shown to contain a mini-loop with a
single histidine residue similar to the occluding loop of ca-
thepsin B with two histidines [30]. Inhibitors 6, 7, and 8 com-
pletely abolished the peptidase activity of the cell lysates mea-
surable with the substrate Z-Phe-Arg-NHMec, but cathepsin
X would not have been detected with this substrate due to its
extremely weak endopeptidase activity [31].
3.5. Conclusions
In conclusion, the parent inhibitor 8 as well as the a⁄nity
labels 6 and 7 represent a novel tool kit that facilitates studies
of extracellular cathepsin B activity in in£ammation, tumor
invasion and metastasis. During preparation of this article,
work on targeting of lysosomal cysteine proteinases by radio-
iodo-labeled epoxysuccinyl peptides derived from CA074 has
been published by Bogyo et al. [32]. By replacement of the n-
propyl moiety by a tryptamine moiety to allow subsequent
labeling with 125I they obtained a non-cell-permeable epoxy-
succinyl peptide (MB-074) with relatively poor a⁄nity in com-
parison with our endo-epoxysuccinyl peptide 8 (MB-074: k2/
Ki = 2750 þ 450; peptide 8 : k2/Ki = 1 520 000 þ 88 800). In con-
trast, our novel design concept (Fig. 1) allows functionaliza-
tion with a wide variety of non-radioactive labels or e¡ector
molecules [19] without loss of inhibitory potency and selectiv-
ity, because interaction of the inhibitor with the active site is
virtually una¡ected by the label that is located outside. In
future, this concept of double-headed epoxysuccinyl peptide
inhibitors may be further exploited to meet the speci¢city
requirements of other cathepsins, particularly cathepsin X.
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Fig. 2. Cell permeability of epoxysuccinyl peptides. A: Residual ca-
thepsin B activity was measured in lysates of MCF-7 breast cancer
cells that had been incubated without or with increasing concentra-
tions (0.1, 1.0, 10, and 50 WM) of the inhibitors 6 (rhodamine B-la-
beled), 7 (biotinylated), and 8 (parent). B: In a control experiment,
lysates of cells pre-incubated without inhibitor were reacted with in-
creasing concentrations (1034, 1033, and 0.1 WM) of inhibitor 8.
The columns represent mean values of three experiments with stan-
dard deviations (bars).
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of MCF-7 cells that had been incubated with di¡erent concentra-
tions of the biotinylated inhibitor 7 (0, 0.1, 1, 10 and 50 WM).
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